Follow

Scandion Oncology A/S

Nasdaq First North GM Stockholm (Sweden)

Scandion Oncology is working to develop treatments that will re-sensitize cancer cells to chemotherapy within metastatic colorectal and pancreatic cancer.
Go to market

Sector:
HEALTH CARE
>
Biotechnology
Healthcare
Rights issue
Price
8.75 SEK
Subscription period
16 Jun - 28 Jun 2022
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Show archived

NB! Information about past events and all documents are available for signed in users who have bought those events.

Type
Ticker
ISIN
Market
SHARE
SCOL
DK0061031895
Nasdaq First North GM Stockholm
Sweden (SE)
Details of share in Scandion Oncology A/S with ticker SCOL
Status
Active
Amount of instruments
32 135 484
Currency
SEK
First trading date
08 Nov 2018
Rights issue
Sign in to buy
Exercise
Sign in to buy
Rights issue
Sign in to buy
Market move
Sign in to buy
Type
Price
Pre-money
Time
Files
Rights issue
8.75 SEK
281.19M SEK
16 Jun - 28 Jun 2022
Share issue in Scandion Oncology A/S
Type
Ticker
ISIN
Market
SHARE
SCOL
DK0061031895
Nasdaq First North GM Stockholm
Sweden (SE)
Details of share in Scandion Oncology A/S with ticker SCOL
Status
Active
Amount of instruments
32 135 484
Currency
SEK
First trading date
08 Nov 2018
Rights issue
Sign in to buy
Rights issue
Sign in to buy
Market move
Sign in to buy
Type
Price
Pre-money
Time
Files
Rights issue
8.75 SEK
281.19M SEK
16 Jun - 28 Jun 2022
Share issue in Scandion Oncology A/S
Type
Ticker
ISIN
Market
OPTION
SCOL TO 1
DK0061144078
Nasdaq First North GM Stockholm
Sweden (SE)
Details of option in Scandion Oncology A/S with ticker SCOL TO 1
Status
Archived
Amount of instruments
2 381 530
Currency
SEK
Trading period
08 Aug 2019 - 29 Sep 2020
Terms
One (1) warrant entitles the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 5.20 per share during the subscription period from September 10, 2020 until October 1, 2020.
Update (05.08.2019): First day of trading in TO 1 in Scandion Oncology.
Update (10.09.2020): The exercise period for warrants in Scandion Oncology A/S begins today.
Update (25.09.2020): Reminder to exercise Scandion Oncology A/S series TO 1 warrants.
Exercise
Sign in to buy
People
Bo Hansen
CEO
Peter Høngaard
Chairman of the board
Annie Rasmussen
Board member
Bo Hansen
Board member
Carl Borrebäck
Board member
Christian Vinding Thomsen
Board member
Jørgen Bardenfleth
Board member
Company Details
Sector
HEALTH CARE

Address
Fruebjergvej 3
Zip code
2100
City/district
Copenhagen
Country
Denmark (DK)
Phones
Registration number
38613391
LEI code
549300MPWDMQ5LZEGD09
First trade date
08 Nov 2018
Registration date
05 Feb 2017
Short name
Scandion Oncology

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More